Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review

作     者：Shuang Wu Tatsuo Kanda Shingo Nakamoto Fumio Imazeki Osamu Yokosuka 

作者机构：Department of Gastroenterology and NephrologyChiba UniversityGraduate School of MedicineChiba 260-8677Japan Postdoctoral FellowForeign Researcher of the Japan Society for Promotion of Science (JSPS)Tokyo 102-0083Japan Department of Molecular VirologyChiba UniversityGraduate School of MedicineChiba 260-8677Japan Safety and Health OrganizationChiba UniversityChiba 263-8522Japan 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2013年第19卷第47期

页      面：8940-8948页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：Supported by Grants from the Japan Society for Promotion of Science(JSPS) Scientific Research from the Ministry of Education,Culture,Sports,Science,and Technology of Japan and Grants from the Ministry of Health,Labour,and Welfare of Japan 

主　　题：Direct-acting antiviral agent Hepatitis C virus Protease inhibitor Resistance mutation Sequence analysis 

摘      要：Direct-acting antiviral agents(DAAs)for hepatitis C virus(HCV)infection are one of the major advances in its medical *** HCV protease inhibitors boceprevir and telaprevir were the first approved DAAs in the United States,Europe,and *** combined with peginterferon plus ribavirin,these agents increase sustained virologic response rates to70%-80%in treatment-na?ve patients and previoustreatment relapsers with chronic HCV genotype 1 *** peginterferon plus ribavirin,DAA monotherapies increased DAA-resistance *** new DAAs for HCV are now in clinical development and are likely to be approved in the near ***,it has been reported that the use of these drugs also led to the emergence of DAA-resistance mutations in certain ***,these mutations exhibit cross-resistance to multiple *** prevalence of DAA-resistance mutations in HCV-infected patients who were not treated with DAAs is unknown,and it is as yet uncertain whether such variants are sensitive to *** performed a population sequence analysis to assess the frequency of such variants in the sera of HCV genotype 1-infected patients not treated with HCV protease ***,we reviewed the literature on resistance variants of HCV protease inhibitors in treatment na?ve patients with chronic HCV genotype 1,as well as our experience.